BioSpace News Archive

Grant to develop the first cell-based and label-free, high-throughput assay of specific enzyme activities.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson (CF102) in the treatment of advanced hepatocellular carcinoma (HCC) in patients whose disease has progressed on sorafenib therapy.

Dicerna Pharmaceuticals, Inc. announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index

Campaign Goes Live in June as part of Company’s “Summer of Impact”

Earnings Call Scheduled for 8:00 a.m. ET on June 27, 2018

New guide for patients addresses growing interest in probiotics

Citius’ Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections

35 Projects Benefit 29 Non-Profits Across Massachusetts, Rhode Island, New Hampshire and Connecticut

3Scan, the world leading 3D tissue data provider and The University of Pittsburgh Medical Center join forces to generate a vast library of tissue data for medical discovery, target identification and therapeutics development

Cronos Group Inc. is pleased to announce that Cronos Australia Pty Ltd. has been granted a medicinal cannabis Manufacture License by the Australian Office of Drug Control.